Table 2:

Univariate Logistic Regression Analyses Identifying Characteristics Associated with Discontinued Treatment Early Compared to Those Treated Continuously

	Odds Ratio*	Lower 95% Confidence Limit	Upper 95% Confidence Limit	P-Value
Baseline Variable
Age, Years	0.93	0.89	0.97	0.0008
Female vs Male	0.64	0.25	1.67	0.37
Race
Black vs White	5.50	1.22	24.61	0.03
Other vs White	5.50	1.41	21.52	0.01
Hispanic ethnicity vs non-hispanic	2.43	0.54	11.03	0.25
CRVO disease type	1.60	0.45	5.66	0.47
Disease duration (months)	0.88	0.76	1.02	0.09
w/ Diabetes vs not	2.84	1.09	7.37	0.03
w/ Hypertensive vs not	1.10	0.39	3.11	0.86
Aflibercept assignment vs bevacizumab	1.05	0.42	2.65	0.91
Prior anti-VEGF treatment vs not	0.36	0.11	1.14	0.08
Visual Acuity Letter Score	0.99	0.96	1.02	0.65
Central Subfield thickness, per 100 μm	1.08	0.90	1.31	0.42
M01 Variables
Delta VALS at M01: 5 – 9 vs < 5 letters	1.00	0.18	5.6	1.00
Delta VALS at M01: > = 10 vs < 5 letters	2.04	0.53	7.79	0.29
CST<300 at M01 vs not	1.01	0.35	2.87	0.99
Complete macular resolution at M01 vs N	1.13	0.41	3.09	0.81
M60 Variables
Visual Acuity Letter Score	1.02	0.99	1.05	0.16
Central Subfield thickness, per 100 μm	0.28	0.09	0.82	0.02
Complete macular resolution at M60 vs N	12.31	4.23	35.79	<.0001

^*Odds Ratio defined as the ratio of the odds of discontinuing treatment early given the presence of the characteristic and the odds of discontinuing treatment early, given the absence of the characteristic. For continuous characteristics, the odds ratio is the odds of treatment discontinuation early for every unit increase with the continuous variable.